Bolt Biotherapeutics, Inc. (BOLT)
4.91
-0.15
(-2.96%)
USD |
NASDAQ |
Nov 20, 16:00
4.91
0.00 (0.00%)
After-Hours: 20:00
Bolt Biotherapeutics Research and Development Expense (TTM) : 16.48M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 16.48M |
| June 30, 2026 | 20.58M |
| March 31, 2026 | 22.76M |
| December 31, 2025 | 27.24M |
| September 30, 2025 | 33.80M |
| June 30, 2025 | 40.90M |
| March 31, 2025 | 48.73M |
| December 31, 2024 | 55.69M |
| September 30, 2024 | 60.22M |
| June 30, 2024 | 61.36M |
| March 31, 2024 | 60.84M |
| December 31, 2023 | 58.21M |
| September 30, 2023 | 58.06M |
| Date | Value |
|---|---|
| June 30, 2023 | 61.42M |
| March 31, 2023 | 64.81M |
| December 31, 2022 | 68.23M |
| September 30, 2022 | 74.13M |
| June 30, 2022 | 74.55M |
| March 31, 2022 | 75.52M |
| December 31, 2021 | 71.98M |
| September 30, 2021 | 64.51M |
| June 30, 2021 | 55.13M |
| March 31, 2021 | 44.92M |
| December 31, 2020 | 37.85M |
| September 30, 2020 | 30.68M |
| June 30, 2020 | 27.58M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Caribou Biosciences, Inc. | 84.72M |
| Oncolytics Biotech, Inc. | 13.18M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 647.26M |
| Anixa Biosciences, Inc. | 4.828M |